Bad medicine the prescription drug industry in the third world
The pharmaceutical industry has long and vehemently insisted that it has the willingness, the dedication, and the ability to police itself to insure that the public will not be unnecessarily harmed or defrauded. As the record shows with painful clarity, however, virtually no industry or professional...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Format: | Buch |
| Sprache: | English |
| Veröffentlicht: |
Stanford, Calif.
Stanford Univ. Press
1992
|
| Schlagworte: | |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
MARC
| LEADER | 00000nam a2200000 c 4500 | ||
|---|---|---|---|
| 001 | BV006628297 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | t | ||
| 008 | 930326s1992 |||| 00||| engod | ||
| 020 | |a 0804716692 |9 0-8047-1669-2 | ||
| 035 | |a (OCoLC)24376708 | ||
| 035 | |a (DE-599)BVBBV006628297 | ||
| 040 | |a DE-604 |b ger |e rakddb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-12 | ||
| 050 | 0 | |a HD9674.D44 | |
| 082 | 0 | |a 338.4/76151/091724 |2 20 | |
| 100 | 1 | |a Silverman, Milton |e Verfasser |4 aut | |
| 245 | 1 | 0 | |a Bad medicine |b the prescription drug industry in the third world |c Milton Silverman ; Mia Lydecker ; Philip R. Lee |
| 264 | 1 | |a Stanford, Calif. |b Stanford Univ. Press |c 1992 | |
| 300 | |a XVII, 359 S. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 520 | 3 | |a The pharmaceutical industry has long and vehemently insisted that it has the willingness, the dedication, and the ability to police itself to insure that the public will not be unnecessarily harmed or defrauded. As the record shows with painful clarity, however, virtually no industry or professional group has ever adequately policed itself, and the pharmaceutical industry is no exception. Where the most flagrant abuses have been exposed and corrected, major credit must probably be divided among the media that publicized the situation, consumer groups that applied pressure, government officials who took actions that were often unpopular, and individual members of the pharmaceutical industry who had the courage to face up to their social responsibilities | |
| 520 | 3 | |a To this number should perhaps be added the three authors of this volume who have, in a series of books such as Pills, Profits, and Politics, The Drugging of America, and Prescriptions for Death: The Drugging of the Third World, exposed fraudulent practices by U.S. and multinational pharmaceutical companies. In this book, the authors turn their attention to what happened in Third World countries when, because of worldwide pressures, the multinational drug companies largely corrected their notorious abuses. On the basis of painstaking research, much of it conducted in a great many Third World countries, the authors conclude that a plethora of small local firms have filled the dishonest sales channels vacated by the multinationals | |
| 520 | 3 | |a The authors show in great detail how local drug firms in the Third World have taken advantage of loose regulatory practices and unscrupulous behavior on the part of regional and national health care professionals to promote the sale of dangerous or worthless drugs as remedies for diseases for which they were never intended. Warnings of bad side effects are omitted from promotional literature, drugs are sold that have not had proper trials, and drug firms have often bribed government officials, doctors, and hospital administrators in order to gain favorable treatment in the importation and sale of their products. Among the many topics treated in this book are the controversy over inexpensive generic drugs (including disclosures of fraud and bribery in the U.S. Food and Drug Administration), the actions of consumer groups, and the key role of government in preventing abuses by drug firms | |
| 650 | 4 | |a Entwicklungsländer | |
| 650 | 4 | |a Developing Countries | |
| 650 | 4 | |a Drug Industry | |
| 650 | 4 | |a Pharmaceutical industry |x Corrupt practices |z Developing countries | |
| 650 | 4 | |a Pharmaceutical policy |z Developing countries | |
| 650 | 4 | |a Social Responsibility | |
| 650 | 0 | 7 | |a Arzneimittelversorgung |0 (DE-588)4140783-0 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Pharmazeutische Industrie |0 (DE-588)4045696-1 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Gesundheitspolitik |0 (DE-588)4113743-7 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Wirtschaftsethik |0 (DE-588)4066439-9 |2 gnd |9 rswk-swf |
| 651 | 7 | |a Entwicklungsländer |0 (DE-588)4014954-7 |2 gnd |9 rswk-swf | |
| 689 | 0 | 0 | |a Entwicklungsländer |0 (DE-588)4014954-7 |D g |
| 689 | 0 | 1 | |a Arzneimittelversorgung |0 (DE-588)4140783-0 |D s |
| 689 | 0 | 2 | |a Gesundheitspolitik |0 (DE-588)4113743-7 |D s |
| 689 | 0 | |5 DE-604 | |
| 689 | 1 | 0 | |a Entwicklungsländer |0 (DE-588)4014954-7 |D g |
| 689 | 1 | 1 | |a Pharmazeutische Industrie |0 (DE-588)4045696-1 |D s |
| 689 | 1 | 2 | |a Wirtschaftsethik |0 (DE-588)4066439-9 |D s |
| 689 | 1 | |5 DE-604 | |
| 700 | 1 | |a Lydecker, Mia |e Verfasser |4 aut | |
| 700 | 1 | |a Lee, Philip R. |e Verfasser |4 aut | |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-004236675 | ||
Datensatz im Suchindex
| _version_ | 1804120905989750784 |
|---|---|
| any_adam_object | |
| author | Silverman, Milton Lydecker, Mia Lee, Philip R. |
| author_facet | Silverman, Milton Lydecker, Mia Lee, Philip R. |
| author_role | aut aut aut |
| author_sort | Silverman, Milton |
| author_variant | m s ms m l ml p r l pr prl |
| building | Verbundindex |
| bvnumber | BV006628297 |
| callnumber-first | H - Social Science |
| callnumber-label | HD9674 |
| callnumber-raw | HD9674.D44 |
| callnumber-search | HD9674.D44 |
| callnumber-sort | HD 49674 D44 |
| callnumber-subject | HD - Industries, Land Use, Labor |
| ctrlnum | (OCoLC)24376708 (DE-599)BVBBV006628297 |
| dewey-full | 338.4/76151/091724 |
| dewey-hundreds | 300 - Social sciences |
| dewey-ones | 338 - Production |
| dewey-raw | 338.4/76151/091724 |
| dewey-search | 338.4/76151/091724 |
| dewey-sort | 3338.4 576151 591724 |
| dewey-tens | 330 - Economics |
| discipline | Wirtschaftswissenschaften |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>04412nam a2200565 c 4500</leader><controlfield tag="001">BV006628297</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">930326s1992 |||| 00||| engod</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0804716692</subfield><subfield code="9">0-8047-1669-2</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)24376708</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV006628297</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakddb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-12</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">HD9674.D44</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">338.4/76151/091724</subfield><subfield code="2">20</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Silverman, Milton</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Bad medicine</subfield><subfield code="b">the prescription drug industry in the third world</subfield><subfield code="c">Milton Silverman ; Mia Lydecker ; Philip R. Lee</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Stanford, Calif.</subfield><subfield code="b">Stanford Univ. Press</subfield><subfield code="c">1992</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XVII, 359 S.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1="3" ind2=" "><subfield code="a">The pharmaceutical industry has long and vehemently insisted that it has the willingness, the dedication, and the ability to police itself to insure that the public will not be unnecessarily harmed or defrauded. As the record shows with painful clarity, however, virtually no industry or professional group has ever adequately policed itself, and the pharmaceutical industry is no exception. Where the most flagrant abuses have been exposed and corrected, major credit must probably be divided among the media that publicized the situation, consumer groups that applied pressure, government officials who took actions that were often unpopular, and individual members of the pharmaceutical industry who had the courage to face up to their social responsibilities</subfield></datafield><datafield tag="520" ind1="3" ind2=" "><subfield code="a">To this number should perhaps be added the three authors of this volume who have, in a series of books such as Pills, Profits, and Politics, The Drugging of America, and Prescriptions for Death: The Drugging of the Third World, exposed fraudulent practices by U.S. and multinational pharmaceutical companies. In this book, the authors turn their attention to what happened in Third World countries when, because of worldwide pressures, the multinational drug companies largely corrected their notorious abuses. On the basis of painstaking research, much of it conducted in a great many Third World countries, the authors conclude that a plethora of small local firms have filled the dishonest sales channels vacated by the multinationals</subfield></datafield><datafield tag="520" ind1="3" ind2=" "><subfield code="a">The authors show in great detail how local drug firms in the Third World have taken advantage of loose regulatory practices and unscrupulous behavior on the part of regional and national health care professionals to promote the sale of dangerous or worthless drugs as remedies for diseases for which they were never intended. Warnings of bad side effects are omitted from promotional literature, drugs are sold that have not had proper trials, and drug firms have often bribed government officials, doctors, and hospital administrators in order to gain favorable treatment in the importation and sale of their products. Among the many topics treated in this book are the controversy over inexpensive generic drugs (including disclosures of fraud and bribery in the U.S. Food and Drug Administration), the actions of consumer groups, and the key role of government in preventing abuses by drug firms</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Entwicklungsländer</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Developing Countries</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug Industry</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmaceutical industry</subfield><subfield code="x">Corrupt practices</subfield><subfield code="z">Developing countries</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmaceutical policy</subfield><subfield code="z">Developing countries</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Social Responsibility</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Arzneimittelversorgung</subfield><subfield code="0">(DE-588)4140783-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Pharmazeutische Industrie</subfield><subfield code="0">(DE-588)4045696-1</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Gesundheitspolitik</subfield><subfield code="0">(DE-588)4113743-7</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Wirtschaftsethik</subfield><subfield code="0">(DE-588)4066439-9</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="651" ind1=" " ind2="7"><subfield code="a">Entwicklungsländer</subfield><subfield code="0">(DE-588)4014954-7</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Entwicklungsländer</subfield><subfield code="0">(DE-588)4014954-7</subfield><subfield code="D">g</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Arzneimittelversorgung</subfield><subfield code="0">(DE-588)4140783-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="2"><subfield code="a">Gesundheitspolitik</subfield><subfield code="0">(DE-588)4113743-7</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="1" ind2="0"><subfield code="a">Entwicklungsländer</subfield><subfield code="0">(DE-588)4014954-7</subfield><subfield code="D">g</subfield></datafield><datafield tag="689" ind1="1" ind2="1"><subfield code="a">Pharmazeutische Industrie</subfield><subfield code="0">(DE-588)4045696-1</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2="2"><subfield code="a">Wirtschaftsethik</subfield><subfield code="0">(DE-588)4066439-9</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lydecker, Mia</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lee, Philip R.</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-004236675</subfield></datafield></record></collection> |
| geographic | Entwicklungsländer (DE-588)4014954-7 gnd |
| geographic_facet | Entwicklungsländer |
| id | DE-604.BV006628297 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-09T16:49:31Z |
| institution | BVB |
| isbn | 0804716692 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-004236675 |
| oclc_num | 24376708 |
| open_access_boolean | |
| owner | DE-12 |
| owner_facet | DE-12 |
| physical | XVII, 359 S. |
| publishDate | 1992 |
| publishDateSearch | 1992 |
| publishDateSort | 1992 |
| publisher | Stanford Univ. Press |
| record_format | marc |
| spelling | Silverman, Milton Verfasser aut Bad medicine the prescription drug industry in the third world Milton Silverman ; Mia Lydecker ; Philip R. Lee Stanford, Calif. Stanford Univ. Press 1992 XVII, 359 S. txt rdacontent n rdamedia nc rdacarrier The pharmaceutical industry has long and vehemently insisted that it has the willingness, the dedication, and the ability to police itself to insure that the public will not be unnecessarily harmed or defrauded. As the record shows with painful clarity, however, virtually no industry or professional group has ever adequately policed itself, and the pharmaceutical industry is no exception. Where the most flagrant abuses have been exposed and corrected, major credit must probably be divided among the media that publicized the situation, consumer groups that applied pressure, government officials who took actions that were often unpopular, and individual members of the pharmaceutical industry who had the courage to face up to their social responsibilities To this number should perhaps be added the three authors of this volume who have, in a series of books such as Pills, Profits, and Politics, The Drugging of America, and Prescriptions for Death: The Drugging of the Third World, exposed fraudulent practices by U.S. and multinational pharmaceutical companies. In this book, the authors turn their attention to what happened in Third World countries when, because of worldwide pressures, the multinational drug companies largely corrected their notorious abuses. On the basis of painstaking research, much of it conducted in a great many Third World countries, the authors conclude that a plethora of small local firms have filled the dishonest sales channels vacated by the multinationals The authors show in great detail how local drug firms in the Third World have taken advantage of loose regulatory practices and unscrupulous behavior on the part of regional and national health care professionals to promote the sale of dangerous or worthless drugs as remedies for diseases for which they were never intended. Warnings of bad side effects are omitted from promotional literature, drugs are sold that have not had proper trials, and drug firms have often bribed government officials, doctors, and hospital administrators in order to gain favorable treatment in the importation and sale of their products. Among the many topics treated in this book are the controversy over inexpensive generic drugs (including disclosures of fraud and bribery in the U.S. Food and Drug Administration), the actions of consumer groups, and the key role of government in preventing abuses by drug firms Entwicklungsländer Developing Countries Drug Industry Pharmaceutical industry Corrupt practices Developing countries Pharmaceutical policy Developing countries Social Responsibility Arzneimittelversorgung (DE-588)4140783-0 gnd rswk-swf Pharmazeutische Industrie (DE-588)4045696-1 gnd rswk-swf Gesundheitspolitik (DE-588)4113743-7 gnd rswk-swf Wirtschaftsethik (DE-588)4066439-9 gnd rswk-swf Entwicklungsländer (DE-588)4014954-7 gnd rswk-swf Entwicklungsländer (DE-588)4014954-7 g Arzneimittelversorgung (DE-588)4140783-0 s Gesundheitspolitik (DE-588)4113743-7 s DE-604 Pharmazeutische Industrie (DE-588)4045696-1 s Wirtschaftsethik (DE-588)4066439-9 s Lydecker, Mia Verfasser aut Lee, Philip R. Verfasser aut |
| spellingShingle | Silverman, Milton Lydecker, Mia Lee, Philip R. Bad medicine the prescription drug industry in the third world Entwicklungsländer Developing Countries Drug Industry Pharmaceutical industry Corrupt practices Developing countries Pharmaceutical policy Developing countries Social Responsibility Arzneimittelversorgung (DE-588)4140783-0 gnd Pharmazeutische Industrie (DE-588)4045696-1 gnd Gesundheitspolitik (DE-588)4113743-7 gnd Wirtschaftsethik (DE-588)4066439-9 gnd |
| subject_GND | (DE-588)4140783-0 (DE-588)4045696-1 (DE-588)4113743-7 (DE-588)4066439-9 (DE-588)4014954-7 |
| title | Bad medicine the prescription drug industry in the third world |
| title_auth | Bad medicine the prescription drug industry in the third world |
| title_exact_search | Bad medicine the prescription drug industry in the third world |
| title_full | Bad medicine the prescription drug industry in the third world Milton Silverman ; Mia Lydecker ; Philip R. Lee |
| title_fullStr | Bad medicine the prescription drug industry in the third world Milton Silverman ; Mia Lydecker ; Philip R. Lee |
| title_full_unstemmed | Bad medicine the prescription drug industry in the third world Milton Silverman ; Mia Lydecker ; Philip R. Lee |
| title_short | Bad medicine |
| title_sort | bad medicine the prescription drug industry in the third world |
| title_sub | the prescription drug industry in the third world |
| topic | Entwicklungsländer Developing Countries Drug Industry Pharmaceutical industry Corrupt practices Developing countries Pharmaceutical policy Developing countries Social Responsibility Arzneimittelversorgung (DE-588)4140783-0 gnd Pharmazeutische Industrie (DE-588)4045696-1 gnd Gesundheitspolitik (DE-588)4113743-7 gnd Wirtschaftsethik (DE-588)4066439-9 gnd |
| topic_facet | Entwicklungsländer Developing Countries Drug Industry Pharmaceutical industry Corrupt practices Developing countries Pharmaceutical policy Developing countries Social Responsibility Arzneimittelversorgung Pharmazeutische Industrie Gesundheitspolitik Wirtschaftsethik |
| work_keys_str_mv | AT silvermanmilton badmedicinetheprescriptiondrugindustryinthethirdworld AT lydeckermia badmedicinetheprescriptiondrugindustryinthethirdworld AT leephilipr badmedicinetheprescriptiondrugindustryinthethirdworld |